FDA Has Concerns About Study of Atricure for Irregular Heartbeat

Oct. 24 (Bloomberg) -- U.S. regulators said they’re concerned about a study on AtriCure Inc.’s alternative during open-heart surgery to treat an irregular heartbeat.

The device system from the West Chester, Ohio-based company to destroy heart tissue during surgery is set to be considered by a Food and Drug Administration advisory panel on Oct. 26.

Link to Company News:{3400398Z US <Equity> CN <GO>} Link to Company News:{ATRC US <Equity> CN <GO>}

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net